Send to

Choose Destination
Metabolism. 1996 Aug;45(8 Suppl 1):24-6.

Improved analogs and novel delivery systems for somatostatin octapeptides.

Author information

Biomeasure Inc., Milford, MA 01757-3650, USA.


Appropriate N-terminus modification can result in somatostatin (SRIF) octapeptide analogs that are both more potent and more selective in vitro for the human SRIF receptor type 2 (hsst2). In addition, these modifications can improve the duration of action and bioavailability of SRIF analogs following parenteral administration, as shown by both pharmacological and distribution studies in vivo with BIM-23190 and BIM-23197 in the rat.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center